Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)

Author:
Publisher website
Google Scholar
Abstract
Thalidomide and its derivatives represent a new class of antineoplastic drugs (IMiDs), which has been especially effective in certain hematologic malignancies. These agents have anti-inflammatory, antiangiogenic, and immunomodulatory properties, and target tumor cells by direct cytotoxicity and indirectly by interfering with several components of the bone marrow microenvironment [1]. Thalidomide analogs that retain antitumor activity equal to or greater than the parent compound, but with less toxicity, have been developed [2]. This paper summarizes what is known about the mechanisms of action of these agents, and recent clinical results. The data suggest that thalidomide analogs will play a major role in the management of certain hematologic neoplasms in the near future.

This publication has 100 references indexed in Scilit: